Introduction {#Sec1}
============

Cariprazine (RGH-188) is an orally active, high-affinity dopamine D~3~ and D~2~ receptor partial agonist with preferential binding to D~3~ receptors (Kiss et al. [@CR23]). A D~3~ strategy for treatment of schizophrenia is based on the brain distribution and putative role of D~3~ receptors (Gross and Drescher [@CR13]); these receptors have high density in the ventral striatum (Gurevich and Joyce [@CR15]), one of the core areas in the pathology of schizophrenia, as well as depression and anxiety. In preclinical models, dopamine D~3~ receptor antagonists reversed cognitive impairment (Laszy et al. [@CR27]; Millan et al. [@CR31]; Sigala et al. [@CR44]) and enhanced locomotor activity of habituated rats (Gyertyán and Sághy [@CR18]; Sautel et al. [@CR40]; Waters et al. [@CR50]), suggesting potential for improving negative symptoms. However, highly selective D~3~ receptor antagonists failed to show antipsychotic efficacy in preclinical models of schizophrenia (Millan et al. [@CR30]; Reavill et al. [@CR38]) suggesting that D~3~ receptor antagonism alone is not sufficient for antipsychotic efficacy.

It has been shown that ∼60--80 % occupancy of dopamine D~2~ receptors is necessary to achieve antipsychotic action in the clinic (Nyberg et al. [@CR34]; Seeman [@CR42]). It has therefore been hypothesized that combined occupancy of dopamine D~3~ and D~2~ receptors may offer distinct advantages over existing antipsychotics with primarily D~2~ receptor antagonism in the treatment of schizophrenia (Gyertyán et al. [@CR19]; Kiss et al. [@CR24]).

In rodent models, cariprazine pretreatment significantly diminished scopolamine- and PCP-induced cognitive deficits (Zimnisky et al. [@CR53]) and stress-induced anhedonia (Gyertyán and Sághy [@CR18]; Sautel et al. [@CR40]; Waters et al. [@CR49]); in knockout mice, these effects were found to be D~3~-receptor dependent (Zimnisky et al. [@CR53]). Cariprazine has also shown clinical potential for treating negative symptoms based on results from a post hoc analysis of a phase II study in patients with schizophrenia (Debelle et al. [@CR4]) as well as recent results from a prospectively defined schizophrenia study of patients with persistent and predominant negative symptoms (Debelle et al. [@CR5]). One study found negative results of D~3~ receptor antagonists in schizophrenia (Redden et al. [@CR39]); however, this study may have been limited by low occupancies at the tested doses (Graff-Guerrero et al. [@CR12]).

Previous in vivo imaging studies exploring the binding profile of cariprazine in humans and nonhuman primates characterized the D~2~ receptor binding profile of cariprazine but were not informative about its D~3~ receptor-binding profile (Seneca et al. [@CR43]). \[^11^C\]-(+)-4-propyl-9-hydroxynaphthoxazine (\[^11^C\]-(+)-PHNO) is a recently developed D~3~/D~2~ agonist positron emission tomography (PET) radioligand with preferential in vivo selectivity for dopamine D~3~ over D~2~ receptors (Gallezot et al. [@CR7]; Ginovart et al. [@CR8]; Graff-Guerrero et al. [@CR11]; Willeit et al. [@CR51]; Wilson et al. [@CR52]). In contrast to previously used tracers like \[^11^C\]raclopride, \[^11^C\]-(+)-PHNO binding is due mostly to D~3~ receptors in the substantia nigra and ventral tegmental area, D~2~ receptors in the dorsal striatum, and a mixture of both types in globus pallidus, ventral striatum, and thalamus. This mixed binding profile can be exploited to infer the occupancy by antipsychotic drugs at D~2~ and D~3~ receptors separately (Girgis et al. [@CR9]; Rabiner et al. [@CR37]; Searle et al. [@CR41]).

The pharmacokinetic (PK) properties of cariprazine in humans are characterized by relatively slow absorption, multi-exponential disposition, and slow elimination with a long terminal elimination half-life (T½). Two major active metabolites, desmethyl cariprazine (DCAR) and di-desmethyl cariprazine (DDCAR), were identified and monitored in clinical studies (Kapás et al. [@CR21]; Mészáros et al. [@CR29]). At steady state, DDCAR is the predominant active moiety, with systemic exposure that is about 2- to 3-fold higher than cariprazine; DCAR systemic exposure is around 30--40 % of parent drug exposure (Nakamura et al. [@CR33]). DCAR and DDCAR have exhibited partial agonist activity at both D~2~ and D~3~ receptors and have displayed 21- and 25-fold selectivity, respectively, for cloned human D~3~ versus D~2L~ receptors (unpublished data) compared with a 6- to 8-fold D~3~ selectivity for the parent compound (Kiss et al. [@CR23]). Moreover, DDCAR also showed somewhat lower intrinsic activity at cloned human D~2~ receptors compared with cariprazine (Tadori et al. [@CR47]). The activity of cariprazine after multiple dosing is, therefore, expected to be attributable to the parent drug and its two active metabolites.

This study was designed to assess the binding and occupancy of cariprazine, DCAR, and DDCAR to D~3~ and D~2~ receptors in various regions of the brain in adult patients with schizophrenia using PET imaging with \[^11^C\]-(+)-PHNO and to assess the relationship between occupancy and plasma concentrations of cariprazine and its two active metabolites.

Materials and methods {#Sec2}
=====================

Clinical study design {#Sec3}
---------------------

This was an open-label, multiple-dose study in patients (ages 18--55 years, inclusive) with a primary diagnosis of schizophrenia according to *Diagnostic and Statistical Manual of Mental Disorders,* Fourth Edition, Text Revision (DSM-IV-TR) (APA [@CR1]) criteria based on the Structured Clinical Interview for the DSM-IV (First et al. [@CR6]). There were three different dosing cohorts with three patients each (Fig. [S1](#Fig5){ref-type="supplementary-material"}); all had initial up-titration to the final dose to improve tolerability. Cohort 1 received 1.5 mg on day 1, 3 mg on day 2, 6 mg once daily (QD) on days 3--4, 9 mg QD on days 5--6, and 12 mg QD on days 7--15. Cohort 2 received 0.5 mg on day 1, 1 mg QD on days 2--4, and 3 mg QD on days 5--15. Cohort 3 received 0.5 mg QD on days 1--4 and 1 mg QD on days 5--15. The study was conducted at the New York State Psychiatric Institute (NYSPI) at Columbia University Medical Center and the Clinical Neuroscience Research Unit (CNRU)/Schizophrenia Research Clinic at Yale University. All PET scans and pharmacokinetic and cerebrospinal fluid (CSF) sample collections were performed at Yale University. PET data analysis was done at Columbia University. The study protocol was approved by the Yale and NYSPI Institutional Review Boards and was conducted in compliance with the ICH Good Clinical Practice guidelines and the Declaration of Helsinki. Patients provided signed informed consent at screening and had the capacity to understand it. Participants were compensated for their participation.

Dynamic PET scans were acquired with \[^11^C\]-(+)-PHNO. A maximum of five PET scans were performed for each patient to evaluate D~3~ and D~2~ receptor occupancy on day 1 at predose (baseline) and 4 h postdose (after plasma PK sampling), on day 4 at 4 h postdose (after plasma PK sampling), on day 15 at 4 h postdose (after plasma PK sampling), and on day 24 after the plasma PK sampling. The average injected radioactivity was 564 ± 157 MBq, specific activity was 80 ± 33 MBq/nmol, and injected mass was 2.0 ± 0.48 μg.

Safety was assessed by adverse event (AE) recording, clinical laboratory tests, vital sign assessments, electrocardiography, physical and psychiatric examinations, and Columbia--Suicide Severity Rating Scale (C-SSRS) (Posner et al. [@CR35]), Clinical Global Impressions--Severity scale (CGI-S) (Guy, [@CR16]), and extrapyramidal symptoms scales (Barnes Akathisia Rating Scale (Barnes [@CR2]), Abnormal Involuntary Movement Scale (Guy [@CR16]), and Simpson-Angus Scale (Simpson and Angus [@CR45])).

Blood sample collection and processing {#Sec4}
--------------------------------------

Blood samples for determining cariprazine, DCAR, and DDCAR concentrations in plasma were collected using a prechilled 4-mL Vacutainer tube (containing K~2~EDTA as an anticoagulant) on days 1/2, 4/5, and 15/16 at 0 h (predose) and 1, 2, 4, 6, 8, 19, and 24 h post days 1, 4, and 15 dosing and on day 24 at 216 h after the day-15 dose; plasma was also collected predose on day 3. Blood samples for PK evaluation were centrifuged within 30 min of drawing at ≥2500*g* for 10 min at 4 °C and the plasma was harvested. After centrifugation, plasma samples were transferred into prechilled, coded polypropylene tubes. Samples were flash-frozen in an isopropyl alcohol/dry ice bath and stored at approximately −70 °C. Additional blood samples were collected for clinical laboratory analysis.

Cerebrospinal fluid collection {#Sec5}
------------------------------

CSF samples were collected on day 3 (predose) and day 16 (approximately 24 h after day-15 dose). Lumbar punctures were performed using standard aseptic technique and a 20-mL Quincke or 25-mL Sprotte needle. A maximum of 10 mL of CSF was collected for PK analyses.

Bioanalytical method {#Sec6}
--------------------

Plasma and CSF concentrations of cariprazine, DCAR, and DDCAR were measured using a liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method, validated to demonstrate the accuracy, linearity, reproducibility, and precision of the analytical procedure. The lower limit of quantitation (LLOQ) for the plasma assay was 20:20:50 pg/mL for cariprazine/DCAR/DDCAR using a plasma sample volume of 200 μL; the LLOQ for the CSF assay was 5:5:10 pg/mL, respectively, using a sample volume of 250 μL.

PET and radiochemistry methods {#Sec7}
------------------------------

\[^11^C\]-(+)-PHNO was prepared by N-acylation of the despropyl precursor with \[^11^C\]-propionyl chloride followed by reduction of the resulting amide with lithium aluminum hydride and purification by reverse-phase high-performance liquid chromatography (HPLC) (Wilson et al. [@CR52]). All scans were 120 min, following a single bolus injection of \[^11^C\]-(+)-PHNO. Data were acquired on a Siemens High-Resolution Research Tomograph (HRRT, Siemens/CTI, Knoxville, TN). Data were acquired in list mode, reconstructed using the MOLAR algorithm (Carson et al. [@CR3]) including correction for subject motion using an optical detection system (Vicra, NDI Systems, Waterloo, Ontario, Canada) and binned into a sequence of 33 frames of increasing duration (6 × 30 s, 3 × 1 min, 2 × 2 min, 22 × 5 min). A T1-weighted anatomical magnetic resonance imaging (MRI) scan was acquired for each subject. Regions of interest (ROIs) were drawn individually for each subject on their MRI; they included caudate and putamen, ventral striatum, globus pallidus, thalamus, substantia nigra/ventral tegmental area, and cerebellum as a reference tissue. Left and right sides were averaged. PET data were coregistered to subjects' MRIs; ROIs were applied to the coregistered PET images. Time activity curves were generated as the average ROI activity in each frame.

Statistical analysis {#Sec8}
--------------------

### Pharmacokinetics {#Sec9}

The principal parameters describing the PK of cariprazine, DCAR, and DDCAR were derived from plasma concentrations using noncompartmental analysis with the validated software program Phoenix WinNonlin version 6.1 (Pharsight, St. Louis, MO). The plasma PK parameters for cariprazine and its metabolites were calculated after dosing on days 1, 4, and 15. Reported parameters included area under the curve (AUC) over 24 h, peak concentration (*C*~max~), time of maximum concentration (*T*~max~), and trough concentration (*C*~min~). Concentration in CSF (*C*~csf~) at 24 h after last dose was also determined.

### PET analysis {#Sec10}

Reference tissue-based kinetic modeling was performed on all data using the basis function version of the simplified reference tissue method (SRTM) (Gunn et al. [@CR14]; Lammertsma and Hume [@CR25]), with cerebellum as the reference tissue. The primary outcome measure was the binding potential relative to the nondisplaceable compartment (BP~ND~) (Innis et al. [@CR20]). The fractional change in BP~ND~ across conditions (∆BP~ND~) was computed as the relative change between baseline BP~ND~ and BP~ND~ during each condition:$$\documentclass[12pt]{minimal}
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∆BP~ND~ data from each condition were entered into a nonlinear regression model to extract the specific contribution of D~2~ and D~3~ receptors (Girgis et al. [@CR9]; Rabiner et al. [@CR37]; Searle et al. [@CR41]). In this model, BP~ND~ in each region is parsed into its D~2~ and D~3~ components from each scan and condition. We defined *f*~D3~ as the fraction of total BP~ND~ attributable to D~3~ binding, which in general, varies across regions but is similar across subjects. Under these assumptions, ∆BP~ND~ following cariprazine is:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \varDelta {BP}_{ND}={f}_{\mathrm{D}3}{OCC}_{\mathrm{D}3}+\left(1-{f}_{\mathrm{D}3}\right){OCC}_{\mathrm{D}2} $$\end{document}$$where OCC~D3~ and OCC~D2~ are the occupancies at D~3~ and D~2~ receptors by cariprazine and its metabolites. For a given scan, OCC~D3~ and OCC~D2~ are treated as equal across brain regions (though not across receptor types), but their values vary across scans. The \[^11^C\]-(+)-PHNO BP~ND~ data were fitted to this equation with ∆BP~ND~ for each scan and region as input to the model. Two methods were applied. In method 1, *f*~D3~ for each region was treated as a fixed parameter according to the values in (Searle et al. [@CR41]), and OCC~D3~ and OCC~D2~ were estimated for each subject and day, obtained as parameter estimates using ordinary linear least squares fitting. In method 2, in addition to the two occupancy parameters, *f*~D3~ was treated as a fitted parameter and all parameters were estimated by nonlinear least squares fitting. In each region, *f*~D3~ was treated as equal across subjects. These fits were done for each day leading to 54 or 60 ∆BP~ND~ dependent variables (10 subjects on day 1, 9 for all other days, 6 regions per subject) and 18 or 20 estimated parameters for method 1 (two occupancies for each subject on that day) or 24 or 26 estimated parameters for method 2 (six *f*~D3~s estimated for the day and two occupancies for each subject on that day). In theory, *f*~D3~ may vary across subjects but estimating it for each subject might require a richer data set (e.g., multiple doses within subject under each condition) to allow reliable estimation. Thus, single values across subjects, whether fixed or fitted, were considered more parsimonious, given the available data and the general consistency of *f*~D3~ observed across primate species and subjects (Rabiner et al. [@CR37]; Searle et al. [@CR41]; Slifstein et al. [@CR46]).

### Pharmacokinetic-pharmacodynamic PET analysis {#Sec11}

The relationships between D~3~ and D~2~ receptor occupancy and plasma levels of cariprazine and its metabolites at the time of PET were explored by fitting the plasma concentration of total active cariprazine (cariprazine + DCAR + DDCAR) versus occupancy data using an *E*~max~ model from the library of pharmacodynamic (PD) models provided within Phoenix WinNonlin (version 6.1):$$\documentclass[12pt]{minimal}
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Results {#Sec12}
=======

Patients {#Sec13}
--------

Nine patients (seven men, two women) aged 24 to 55 years were enrolled. One patient (cohort 1) experienced emesis on day 4 and withdrew; this subject's day 1 data were included in the analysis.

Pharmacokinetics {#Sec14}
----------------

Plasma concentrations of cariprazine, DCAR, and DDCAR in cohort 1 are presented in Fig. [1](#Fig1){ref-type="fig"}. Total active cariprazine during the 24-h interval after day-1 dosing consists primarily of parent drug; exposure of the DCAR metabolite slowly increased, while plasma concentration of the DDCAR metabolite was below the LLOQ of the bioanalytical assay (Fig. [1](#Fig1){ref-type="fig"}a). After subchronic dosing (15 days), plasma active drug level consisted primarily of cariprazine and DDCAR, while DCAR level was substantially lower (AUC ∼25--40 % of parent drug exposure) (Fig. [1](#Fig1){ref-type="fig"}b). On day 24, 9 days following the final dose, plasma levels of cariprazine and DCAR decreased substantially, while DDCAR level decreased to a smaller extent (from 21.22 ng/ml at 24 h post day-15 dose to 13.11 ng/mL on day 24), suggesting a longer half-life (Fig. [1](#Fig1){ref-type="fig"}c).Fig. 1Plasma concentration (mean ± SD) of cariprazine and its metabolites as a function of time in cohort 1. Cohort 1 received one 1.5 mg tablet on day 1, 3 mg on day 2, 6 mg once daily on days 3--4, 9 mg once daily on days 5--6, and 12 mg once daily on days 7--15. The concentration versus time profiles for all three active moieties of cariprazine are shown during the 24-h interval after dose on day 1 (**a**), during the 24-h interval after dose on day 15 (**b**), and interval from days 1 to 24 (with last dose administered on day 15) (**c**)

Because the three cohorts had different periods of dose up-titration to improve drug tolerability, results are presented separately by day of treatment (Supplemental Table [1](#MOESM2){ref-type="media"}). Plasma exposure (*C*~max~, *C*~min~, and AUC) of all three components, in general, increased with dose and were consistent with dose proportional PK by day 15.

In all three cohorts, mean CSF concentrations of DCAR and DDCAR 24 h after the final dose ranged from 18 to 35 and 94--120 %, respectively, of those of cariprazine (Supplemental Table [1](#MOESM2){ref-type="media"}); corresponding mean plasma trough (*C*~min~) concentrations of DCAR and DDCAR (based on nM concentrations) were 29--53 and 139--203 %, respectively, of those of cariprazine. On average, concentrations of cariprazine, DCAR, and DDCAR in CSF were approximately 5--10, 4--6, and 3--8 % of the respective concentrations in plasma.

PET results {#Sec15}
-----------

Figure [2](#Fig2){ref-type="fig"} shows ∆BP~ND~ by condition and dose for each region. Under each dosing condition (acute, day 4/5, subchronic), there was a clear dose response, with the magnitude of ∆BP~ND~ increasing as a function of dose. Both occupancy models gave similar results for subchronic dosing, but model 2 did not reliably estimate *f*~D3~ on days 1 and 4 due to the similarity of occupancy at both receptor types at these times; therefore, we report method 1 results only (*f*~D3~ fixed to literature values). Figure [3](#Fig3){ref-type="fig"} depicts the receptor occupancies at D~3~ and D~2~ receptors in each cohort and at each time of the PET measurement. In all three cohorts, receptor occupancies increased from days 1 to 4 to 15 as the doses were increased with initial slow up-titration, and decreased from days 15 to 24 following cessation of cariprazine administration. A monotonic dose-occupancy relationship was observed at both receptor types, with days 4, 15, and 24 following the order occupancy (cohort 1) \> occupancy (cohort 2) \> occupancy (cohort 3). Near-complete (100 %) receptor occupancy at both receptor types was observed at 12 mg/day on day 15. At the lowest dose of 1 mg/day, mean D~3~ and D~2~ receptor occupancy on day 15 was 76 % (range 58--89 %) and 45 % (range, 14--64 %), respectively. At the intermediate 3-mg/day dose, mean D~3~ and D~2~ receptor occupancies were 92 % (range, 86--96 %) and 79 % (range, 68--88 %), respectively. Occupancy was reduced in all brain regions in all three cohorts 9 days after the last dose of cariprazine, suggesting reversibility of receptor binding. Mean receptor occupancy decreased from 76 % (range, 58--89 %) to 20 % (range, −2 to 31 %) for D~3~ and 45 % (range, 14--64 %) to 32 % (range, 23--48 %) for D~2~ between days 15 and 24 in cohort 3 after 1 mg of final daily dosing. Similarly, at the final dose of 3 mg in cohort 2, mean receptor occupancy decreased from 92 to 54 % for D~3~ and 79 to 40 % for D~2~. At the highest dose of 12 mg, drug exposure resulted in complete occupancy for both receptor types and did not decrease substantially even after 9 days of drug washout (D~3~ from 99 to 97 % and D~2~ from 95 to 77 %) suggesting that high levels of active drug were still present 9 days after the 12-mg dose on day 15.Fig. 2The percent decrease in binding potential (∆BP~ND~) by day and dose. *Error bars* are standard deviations. Acute doses were 1.5 mg (*n* = 3) and 0.5 mg (*n* = 6). Day 4/5 doses (day 4, *n* = 7; day 5, *n* = 1) were 6 mg (*n* = 2), 1 mg (*n* = 3), and 0.5 mg (*n* = 3). Subchronic doses (day 15, *n* = 6; day 11, *n* = 1, day 17, *n* = 1) were 12 mg (*n* = 2), 3 mg (*n* = 3), and 1 mg (*n* = 3). *GP* globus pallidus, *PUT* putamen, *CAD* caudate nucleus, *VST* ventral striatum, *THAL* thalamus, *SN/VTA* substantia nigra/ventral tegmental areaFig. 3Occupancy estimates on different days of dosing using fixed literature values for the D~3~ fraction of regional \[^**11**^ **C**\]-(+)-PHNO BP~ND~ (method 1)

ED~50~ estimates and 95 % confidence intervals (CIs) for acute (day 1/4) and subchronic (day 15) doses were 1.52 (0.76, 3.05) and 0.30 (0.15, 0.59) mg for D~3~ occupancy and 1.84 (1.41, 2.40) and 1.03 (0.54, 2.05) mg for D~2~ occupancy using method 1. One subject taking 12 mg/day had a D~3~ occupancy estimate that exceeded 100 %. As a result, the dose-occupancy relationship for subchronic administration was also fitted with the D~3~ occupancy estimate from this subject constrained to 100 % and with the subject's data dropped; this had a negligible effect on the estimated D~3~ ED~50~ for cariprazine, with values of 0.3049 and 0.3064 mg, respectively, compared to 0.3018 mg using the original data. The D~3~ versus D~2~ receptor selectivity ratio of cariprazine treatment was more apparent following subchronic dosing (range, 3.43--5.75) than after an acute dose (range, 1.21--1.31), and was similar for both methods. Selectivity estimates for D~3~ compared with D~2~ overall ranged from about 3- to 6-fold after subchronic dosing.

Pharmacokinetic-pharmacodynamic analyses {#Sec16}
----------------------------------------

Occupancy at D~3~ and D~2~ receptors and plasma concentrations of total active cariprazine (cariprazine + DCAR + DDCAR) at the time of the PET scans (4 h postadministration) following acute (days 1 and 4) and subchronic treatment (day 15) were fitted to an *E*~max~ model (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Receptor occupancy versus total active cariprazine in plasma after dosing on days 1, 4, and 15 fitted to an *E* ~max~ model. D~3~ and D~2~ receptor occupancies versus total active cariprazine plasma concentration are shown after acute treatment (**a**, **b**) and subchronic treatment (**c**, **d**)

The slope for receptor occupancy was quite steep after acute dosing for both receptors suggesting relatively small drug concentration necessary to occupy both receptors. The EC~50~ (± SE) was similar between the two receptors (D~3~ = 1.42 \[0.37\] nM and D~2~ = 1.77 \[0.39\] nM) with a ratio of D~3~/D~2~ of about 1.25, consistent with that observed from ED~50~ analysis.

PK-PD analysis of data collected after subchronic administration (15-day dosing) allowed more time for equilibration between plasma and brain regions, as well as accumulation of slow-forming active metabolite(s), DDCAR in particular. This demonstrated EC~50~ (± SE) estimates for D~3~ and D~2~ receptor-rich regions of 3.84 (1.85) and 13.03 (6.8) nM, respectively. The ratio of EC~50~ for D~3~/D~2~ receptor occupancy of 3.4 suggests preferred affinity at D~3~ compared to D~2~ receptors after multiple-daily dosing of cariprazine for about 2 weeks.

Discussion {#Sec17}
==========

The objectives of this study were to assess D~3~ and D~2~ receptor occupancy of cariprazine and its two major active metabolites, DCAR and DDCAR, in patients with schizophrenia using \[^11^C\]-(+)-PHNO PET imaging, and to explore the relationship between plasma concentrations of cariprazine/DCAR/DDCAR and D~3~ and D~2~ receptor occupancy.

Cariprazine was well absorbed following oral administration. Following the first dose, cariprazine was the most prominent moiety in plasma. The mean plasma AUC of cariprazine on day 1 was 5- to 10-fold higher than the desmethyl metabolite DCAR. The di-desmethyl metabolite DDCAR was not measurable after the first dose on day 1. After 2 weeks of multiple-dose administration, DDCAR and cariprazine were the most prominent moieties in plasma; hence, DDCAR may be responsible for a significant portion of the pharmacological activity of cariprazine following chronic oral administration. In vitro plasma protein binding in various species (including human) is about 96 % (data on file). The concentrations of cariprazine, DCAR, and DDCAR in CSF in this study were 5--10, 4--6, and 3--8 % of the respective concentrations in plasma. The CSF/plasma ratio observed in this study was comparable to the free fraction in plasma (∼4 %), indicating equilibration of free drug and its active metabolites across the blood-brain barrier between plasma and CSF compartments.

The observed PET data show that in patients with schizophrenia, cariprazine robustly binds to both D~3~ and D~2~ receptors, and is moderately D~3~-preferring following subchronic (15-day) dosing with ED~50~ and EC~50~ ratios in the three to six range. These results are consistent with preclinical studies showing binding to both D~3~ and D~2~ receptors in vivo (Gyertyán et al. [@CR17]) and preferential binding to D~3~ receptors in vitro (Kiss et al. [@CR23]) as well as PET studies in nonhuman primates (Seneca et al. [@CR43]; Toth et al. [@CR48]) and humans (Keator et al. [@CR22]; Laszlovszky et al. [@CR26]; Potkin et al. [@CR36]) showing that cariprazine binds to D~2~ receptors. However, these prior PET studies were performed with \[^11^C\]raclopride and \[^18^F\]fallypride, and did not allow for separate assessment of D~3~ and D~2~ receptor binding. In addition, the maximum cariprazine doses in the two prior human studies (1.0 and 3.0 mg) were lower than doses investigated in clinical efficacy studies.

Both ED~50~ and EC~50~ demonstrated comparable D~3~/D~2~ receptor selectivity after acute drug administration (days 1 and 4), while 2 weeks of daily dosing showed 3- to 6-fold higher selectivity (lower EC~50~ and ED~50~) for D~3~ over D~2~ receptors. The D~3~ receptor-preferring nature of cariprazine and its metabolites following subchronic dosing was similar using either method that was tested (methods 1 or 2). Lower selectivity following acute dosing may be due in part to rapid changes in drug and metabolite levels in the body during this transient period, but additionally, the metabolites of cariprazine are more D~3~ receptor preferring than cariprazine itself. In vitro, DCAR is approximately 2-fold more potent than cariprazine at human D~3~ receptors and DDCAR displayed somewhat lower affinity (∼2-fold) than cariprazine at human D~2~ receptors (Tadori et al. [@CR47]). Considering the contribution of DDCAR to total active cariprazine was greater after 2 weeks of dosing than after the initial dose on day 1, the differential affinities of these moieties may help explain the greater selectivity for D~3~ receptors after subchronic dosing. The active metabolite, DDCAR, is formed slowly and takes a few weeks to reach steady state. In order to improve tolerability in patients with schizophrenia, clinical studies with longer treatment duration utilized a dose up-titration during the first week of treatment. During up-titration, cariprazine levels increased rapidly and contributed to the immediate pharmacological effect. It took about 3 weeks to achieve 90 % of steady state for total active cariprazine concentration and 4 weeks for DDCAR; at steady state, about 70 % of the total active concentration comprised the metabolite DDCAR with cariprazine and DCAR contributing the remaining 20 and 10 %, respectively (Nakamura et al. [@CR33]). Hence, the complex PK and differential receptor affinities of cariprazine and its two major metabolites result in rapid onset of pharmacological effect mostly by the parent cariprazine during the first week of treatment followed by a sustained maintenance of anti-D~3~/D~2~ activity by the longer acting metabolite, DDCAR, following chronic dosing. The D~3~/D~2~ binding profiles of the metabolites may also explain why D~3~ receptor binding of cariprazine is sustained and increases with subchronic dosing, while currently available antipsychotic agents seem to bind to D~3~ receptors in expected proportions after acute dosing (Girgis et al. [@CR10]) but not after subchronic dosing (Graff-Guerrero et al. [@CR11]; McCormick et al. [@CR28]; Mizrahi et al. [@CR32]).

Limitations of this study include the relatively small sample size, different dosing schedules, and the fact that we could only measure occupancy for cariprazine and its metabolites combined without estimating their individual contributions. However, these limitations do not prevent clear interpretation of the main results.

In conclusion, this PET imaging study using \[^11^C\]-(+)-PHNO in patients with schizophrenia demonstrated that cariprazine and/or its metabolites bind robustly to dopamine D~2~ and D~3~ receptors in vivo; this binding is moderately D~3~ receptor-preferring, with ED~50~ and EC~50~ ratios in the 3- to 6-fold range. All currently available antipsychotic medications in the USA are more selective for D~2~ than D~3~ receptors. Evidence from animal models suggests that combining potent D~3~ with D~2~ receptor antagonism resulting in high brain occupancy and effective modulation of both receptors may yield antipsychotic compounds with a better profile for improving negative symptoms as well as cognitive deficits (Gyertyán et al. [@CR19]; Kiss et al. [@CR24]). Cariprazine, with its D~3~-preferring profile, may provide a new treatment option for patients with schizophrenia, with a potential for advantages in treating negative symptoms and cognitive impairment.
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